Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18,648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults.
Pene Dumitrescu T, Joshi SR, Xu J, Greene TJ, Johnson M, Butcher L, Zimmerman E, Webster L, Pham TT, Lataillade M, Min S. Pene Dumitrescu T, et al. Among authors: johnson m. Br J Clin Pharmacol. 2021 Sep;87(9):3501-3507. doi: 10.1111/bcp.14759. Epub 2021 Mar 4. Br J Clin Pharmacol. 2021. PMID: 33533507 Free PMC article. Clinical Trial.
The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects.
Johnson M, Jewell RC, Peppercorn A, Gould E, Xu J, Lou Y, Davies M, Baldwin S, Tenorio AR, Burke M, Jeffrey J, Johns BA. Johnson M, et al. Pharmacol Res Perspect. 2018 Jun 5;6(4):e00408. doi: 10.1002/prp2.408. eCollection 2018 Jul. Pharmacol Res Perspect. 2018. PMID: 29930812 Free PMC article. Clinical Trial.
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.
DeJesus E, Harward S, Jewell RC, Johnson M, Dumont E, Wilches V, Halliday F, Talarico CL, Jeffrey J, Gan J, Xu J, Felizarta F, Scribner A, Ramgopal M, Benson P, Johns BA. DeJesus E, et al. Among authors: johnson m. Clin Infect Dis. 2020 Aug 22;71(5):1255-1262. doi: 10.1093/cid/ciz938. Clin Infect Dis. 2020. PMID: 31769793 Clinical Trial.
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
Pene Dumitrescu T, Joshi SR, Xu J, Zhan J, Johnson M, Butcher L, Zimmerman E, Webster L, Davidson AM, Lataillade M, Min S. Pene Dumitrescu T, et al. Among authors: johnson m. Antimicrob Agents Chemother. 2021 May 18;65(6):e02173-20. doi: 10.1128/AAC.02173-20. Print 2021 May 18. Antimicrob Agents Chemother. 2021. PMID: 33753329 Free PMC article. Clinical Trial.
Lack of pharmacokinetic interaction between the HIV-1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women.
Pene Dumitrescu T, Greene TJ, Joshi SR, Xu J, Johnson M, Halliday F, Butcher L, Zimmerman E, Webster L, Pham TT, Lataillade M, Min S. Pene Dumitrescu T, et al. Among authors: johnson m. Br J Clin Pharmacol. 2022 Feb;88(4):1704-1712. doi: 10.1111/bcp.15051. Epub 2021 Sep 21. Br J Clin Pharmacol. 2022. PMID: 34427938 Free PMC article.
18,648 results
You have reached the last available page of results. Please see the User Guide for more information.